- MediciNova ( NASDAQ: MNOV ) said that a phase 2b trial of MN-166 (ibudilast) to treat alcohol use disorder (AUD) has completed enrollment.
- The study enrolled 102 men and women who took MN-166 (ibudilast) 50 mg or placebo twice a day for 12 weeks.
- The main goal of the trial is to evaluate if MN-166 will decrease percent heavy drinking days (defined as ?5 drinks for men and ?4 drinks for women) compared to placebo, over 12 weeks.
- The trial was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the NIAAA R01 research funding was awarded to Principal Investigator Lara Ray, the company added.
- "Recent studies of MN-166 (ibudilast) have shown it to be a safe and promising compound for the treatment of AUD and we are eager to begin the analysis," said Ray.
- MediciNova noted that it provided drug supply and regulatory support for the trial.
For further details see:
MediciNova completes enrollment in mid-stage study of drug for alcohol use disorder